Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Pfizer

Status and phase: Completed; Phase 3

Conditions: Infections, Nosocomial

Treatments: Drug: linezolid

Study type: Interventional

Funder types: Industry

Identifiers

NCT00150332

A5951054

M12600067

Details and patient eligibility

About

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

Enrollment: 24 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• infection due to methicillin-resistant Staphylococcus aureus

Exclusion criteria

• hypersensitivity to linezolid

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)